Table 3. Overall incidence of major outcomes after the index SVT.

	Events, n (%)	Incidence rate per 100 pt-years (95% CI)
Thrombotic events	31 (17.1)	4.2 (2.9–5.9)
Venous thrombosis	19 (10.5)	2.5 (1.6–4.0)
Recurrent SVT		1.9 (1.1–3.1)
Hepatic vein thrombosis	3 (1.7)
Portal vein thrombosis	4 (2.2)
Mesenteric vein thrombosis	6 (3.1)
Splenic vein thrombosis	1 (0.6)
Venous thrombosis at other sites		0.6 (0.2–1.5)
DVT	2 (1.1)
PE	2 (1.1)
Cerebral vein thrombosis	1 (0.6)
Arterial thrombosis	10 (5.5)	1.3 (0.7–2.4)
Unstable angina	1 (0.6)
Myocardial infarction	2 (1.1)
Ischaemic stroke	3 (1.7)
Peripheral artery thrombosis	3 (1.7)
Retinal artery thrombosis	1 (0.6)
Not specified	2 (1.1)
Major bleeding	16 (8.8)	2.1 (1.3–3.5)
CNS	4 (2.2)
Gastrointestinal	6 (3.1)
Muscle hematoma	2 (1.1)
Unspecified	4 (2.2)
Hematologic evolutions	15 (8.3)	2.0 (1.2–3.3)
MF	11 (6.1)
AML	4 (2.2)
Solid cancer	4 (2.2)	0.5 (0.2–1.3)
Brain glioblastoma	1 (0.5)
Breast cancer	1 (0.5)
Nose skin cancer	1 (0.5
Pancreas cancer	1 (0.5)
Deaths	14 (7.7)	1.9 (1.1–3.1)
ICH	1 (0.6)
Infection	1 (0.6)
MF	1 (0.6)
AML	4 (2.2)
Solid tumour	2 (1.1)
Other	2 (1.1)
Unknown	3 (1.7)

Abbreviations: AML, acute myeloid leukemia; CI, confidence interval; CNS, central nervous system; DVT, deep vein thrombosis; ICH, intracranial haemorrhage; MF, myelofibrosis; PE, pulmonary embolism; pt-years, patient years; SVT, splanchnic vein thrombosis